课题基金 / 基金详情

Understanding Hemotopoietic Neoplasias using Humanized Mice

Understanding Hemotopoietic Neoplasias using Humanized Mice
使用人源化小鼠了解造血肿瘤
批准号:
8716691
负责人:
MADHAV V DHODAPKAR
金额:
$96.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-29 至 2015-08-31

项目摘要

项目成果

MADHAV V DHODAPKAR的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ultimate interest of biomedical research is the study of humans and the goal is the improvement of human health. However, research on humans is severely compromised by the inability to perform invasive experimental work in order to establish the cause and effect relationships between processes. Mouse models play an important role in characterizing key aspects of the driving forces of malignant transformation and disease in humans. However, they rarely represent the genetic complexity and clinicopathologic characteristics of human disease. Xenotransplantation of human cells into mice is regularly used to study the biology of human cancer and test the efficacy of novel anti-cancer therapies in vivo. But its value is limited because scientists are currently mainly limited to aggressively growing primary tumors or cell lines that are less susceptible to xenorejection and less dependent on critical signals provided by the microenvironment. Therefore there is an unmet need to develop methods to reliably grow primary human tumor cells in mice. In the here proposed project, humanization of the microenvironment will be achieved by replacement and controlled expression of essential, but not cross-reactive, growth and survival factors in the mouse genome with their human counterparts. Furthermore, novel approaches to reduce xenorejection by myeloid cells and to generate space in the bone marrow niche complete the proposed genetic manipulations. These novel in vivo models will then be used to test and compare as a benchmark acute myeloid leukemia (AML) engraftment, and to establish models for primary chronic myeloid leukemia and myeloproliferative neoplasias, as well as multiple myeloma - diseases in which the lack of in vivo models faithfully reflecting these diseases curtails research. Successful establishment of these models would allow detailed studies of biology as well as validation of approved and experimental therapies. The development of a versatile platform allowing the study of human primary malignancies in vivo in genetically modified mice would represent a major advance for the field. In summary, this model will serve as platform for preclinical therapy testing with increased predictive value and allow studies on biology of the dynamic evolution of neoplasias with an immediate impact on clinical practice.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1146/annurev-immunol-032712-095921
发表时间: 2013
期刊: Annual review of immunology
影响因子: 29.7
作者: [Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA, Manz MG]
通讯作者: Manz MG
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
  • 批准号:
    10222316
  • 项目类别:
  • 资助金额:
    $396.34万
  • 财政年份:
    2020
  • 负责人:
    MADHAV V DHODAPKAR
  • 依托单位:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
  • 批准号:
    10706730
  • 项目类别:
  • 资助金额:
    $54.51万
  • 财政年份:
    2020
  • 负责人:
    MADHAV V DHODAPKAR
  • 依托单位:
Project-004
  • 批准号:
    10705953
  • 项目类别:
  • 资助金额:
    $19.95万
  • 财政年份:
    2020
  • 负责人:
    MADHAV V DHODAPKAR
  • 依托单位:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
  • 批准号:
    10855034
  • 项目类别:
  • 资助金额:
    $305.75万
  • 财政年份:
    2020
  • 负责人:
    MADHAV V DHODAPKAR
  • 依托单位:
海外基金